PortfoliosLab logoPortfoliosLab logo
APLS vs. ADI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

APLS vs. ADI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Apellis Pharmaceuticals, Inc. (APLS) and Analog Devices, Inc. (ADI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

The year-to-date returns for both stocks are quite close, with APLS having a 63.34% return and ADI slightly lower at 62.33%.


APLS

1D
0.00%
1M
0.15%
YTD
63.34%
6M
93.08%
1Y
118.01%
3Y*
-22.49%
5Y*
-1.50%
10Y*

ADI

1D
3.42%
1M
10.54%
YTD
62.33%
6M
58.78%
1Y
103.99%
3Y*
36.71%
5Y*
23.53%
10Y*
24.70%
*Multi-year figures are annualized to reflect compound growth (CAGR)

APLS vs. ADI - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
APLS
Apellis Pharmaceuticals, Inc.
63.34%-21.28%-46.69%15.76%9.37%-17.34%86.81%132.15%-39.22%54.67%
ADI
Analog Devices, Inc.
62.33%29.75%8.82%23.36%-4.91%20.96%26.87%41.31%-1.64%-0.22%

Correlation

The correlation between APLS and ADI is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.18

Correlation (5Y)
Calculated over the trailing 5-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Nov 10, 2017

0.26

The correlation between APLS and ADI shifts across timeframes, from 0.11 (1 year) to 0.26 (all time), reflecting how their relationship changes across market environments.

Fundamentals

EPS

APLS:

$1.41

ADI:

$6.72

PE Ratio

APLS:

29.10

ADI:

65.12

PS Ratio

APLS:

3.77

ADI:

16.94

Total Revenue (TTM)

APLS:

$1.03B

ADI:

$12.74B

Gross Profit (TTM)

APLS:

$920.13M

ADI:

$8.22B

EBITDA (TTM)

APLS:

$176.85M

ADI:

$6.19B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

APLS vs. ADI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

APLS
APLS Risk / Return Rank: 8585
Overall Rank
APLS Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
APLS Sortino Ratio Rank: 9393
Sortino Ratio Rank
APLS Omega Ratio Rank: 9595
Omega Ratio Rank
APLS Calmar Ratio Rank: 8484
Calmar Ratio Rank
APLS Martin Ratio Rank: 8282
Martin Ratio Rank

ADI
ADI Risk / Return Rank: 9595
Overall Rank
ADI Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
ADI Sortino Ratio Rank: 9595
Sortino Ratio Rank
ADI Omega Ratio Rank: 9393
Omega Ratio Rank
ADI Calmar Ratio Rank: 9494
Calmar Ratio Rank
ADI Martin Ratio Rank: 9494
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

APLS vs. ADI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and Analog Devices, Inc. (ADI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


APLSADIDifference

Sharpe ratio

Return per unit of total volatility

0.99

3.39

-2.40

Sortino ratio

Return per unit of downside risk

3.67

4.25

-0.58

Omega ratio

Gain probability vs. loss probability

1.58

1.52

+0.05

Calmar ratio

Return relative to maximum drawdown

3.37

6.65

-3.28

Martin ratio

Return relative to average drawdown

7.45

18.71

-11.26

APLS vs. ADI - Sharpe Ratio Comparison

The current APLS Sharpe Ratio is 0.99, which is lower than the ADI Sharpe Ratio of 3.39. The chart below compares the historical Sharpe Ratios of APLS and ADI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


APLSADIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.99

3.39

-2.40

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.02

0.72

-0.74

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.76

Sharpe Ratio (All Time)

Calculated using the full available price history

0.16

0.34

-0.18

Drawdowns

APLS vs. ADI - Drawdown Comparison

The maximum APLS drawdown since its inception was -82.47%, roughly equal to the maximum ADI drawdown of -82.88%. Use the drawdown chart below to compare losses from any high point for APLS and ADI.


Loading charts...

Drawdown Indicators


APLSADIDifference

Max Drawdown

Largest peak-to-trough decline

-82.47%

-82.88%

+0.41%

Max Drawdown (1Y)

Largest decline over 1 year

-43.53%

-15.73%

-27.80%

Max Drawdown (3Y)

Largest decline over 3 years

-82.47%

-32.20%

-50.27%

Max Drawdown (5Y)

Largest decline over 5 years

-82.47%

-32.20%

-50.27%

Max Drawdown (10Y)

Largest decline over 10 years

-33.62%

Current Drawdown

Current decline from peak

-56.03%

0.00%

-56.03%

Average Drawdown

Average peak-to-trough decline

-37.13%

-33.93%

-3.20%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.63%

5.58%

+14.05%

Volatility

APLS vs. ADI - Volatility Comparison

The current volatility for Apellis Pharmaceuticals, Inc. (APLS) is 0.54%, while Analog Devices, Inc. (ADI) has a volatility of 12.61%. This indicates that APLS experiences smaller price fluctuations and is considered to be less risky than ADI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


APLSADIDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.54%

12.61%

-12.07%

Volatility (6M)

Calculated over the trailing 6-month period

91.44%

23.79%

+67.65%

Volatility (1Y)

Calculated over the trailing 1-year period

147.98%

30.90%

+117.08%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.01%

32.91%

+58.10%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.60%

32.67%

+50.93%

Dividends

APLS vs. ADI - Dividend Comparison

APLS has not paid dividends to shareholders, while ADI's dividend yield for the trailing twelve months is around 1.18%.


PositionTTM20252024202320222021202020192018201720162015
ADI
Analog Devices, Inc.
1.18%1.46%1.73%1.73%1.85%1.57%1.68%1.82%2.24%2.02%2.31%2.89%
APLS
Apellis Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

APLS vs. ADI - Financials Comparison

This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and Analog Devices, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B20222023202420252026
192.01M
3.62B
(APLS) Total Revenue
(ADI) Total Revenue
Values in USD except per share items

APLS vs. ADI - Profitability Comparison

The chart below illustrates the profitability comparison between Apellis Pharmaceuticals, Inc. and Analog Devices, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
78.9%
67.3%
Portfolio components
APLS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a gross profit of 151.46M and revenue of 192.01M. Therefore, the gross margin over that period was 78.9%.

ADI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Analog Devices, Inc. reported a gross profit of 2.44B and revenue of 3.62B. Therefore, the gross margin over that period was 67.3%.

APLS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported an operating income of 26.47M and revenue of 192.01M, resulting in an operating margin of 13.8%.

ADI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Analog Devices, Inc. reported an operating income of 1.38B and revenue of 3.62B, resulting in an operating margin of 38.1%.

APLS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a net income of 18.66M and revenue of 192.01M, resulting in a net margin of 9.7%.

ADI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Analog Devices, Inc. reported a net income of 1.18B and revenue of 3.62B, resulting in a net margin of 32.5%.


Frequently Asked Questions


APLS and ADI have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ADI has higher volatility (12.61%) compared to APLS (0.54%). In terms of maximum drawdown, APLS dropped -82.47% vs ADI's -82.88%.

ADI currently has the higher Sharpe Ratio (3.39 vs 0.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for APLS and ADI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer